ADISSP Drives Metabolic Reprogramming and Immune Suppression to Regulate Hepatocellular Carcinoma Progression and Immunotherapy Sensitivity
Advanced Science · 2026-11-10
DOI: 10.1002/advs.78582 ↗At a glance
Journal article in Advanced Science, published online on 2026-11-10. Written by Tuan-Song Zhang and 10 co-authors. Institution: Shandong Key Laboratory of Malignant Tumor Precision Treatment, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China. 38 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Taishan Scholars Program of Shandong Province, Shandong Provincial Natural Science Foundation.
Abstract (original language)
Metabolic reprogramming and immune evasion are critical drivers of hepatocellular carcinoma (HCC) progression and therapeutic resistance, yet the upstream regulators linking these processes remain poorly understood. Here, we identify adipogenesis‐associated secreted signaling protein (ADISSP) as a previously unrecognized oncogenic regulator in HBV‐related HCC. ADISSP was markedly upregulated in HCC tissues and associated with poor prognosis, while its inhibition suppressed tumor progression in vitro and in vivo. Mechanistically, ADISSP interacted with PPP1CA to sustain NF‐κB activation, resulting in transcriptional induction of SLC16A3 and CCL20. The ADISSP/SLC16A3 axis promoted glycolytic adaptation and lactate‐mediated STAT3 activation, thereby driving macrophage M2 polarization, whereas CCL20 facilitated macrophage recruitment. Together, these pathways established an immunosuppressive tumor microenvironment characterized by enhanced M2 macrophage infiltration and impaired antitumor immunity. More important, targeting ADISSP markedly enhanced the therapeutic efficacy of anti‐PD‐1 plus lenvatinib in HCC. Collectively, our findings identify ADISSP as a central regulator integrating metabolic reprogramming and immune suppression through the PPP1CA/NF‐κB axis and highlight ADISSP as a potential therapeutic target for increasing immunotherapy sensitivity in HCC.
Subjects
Author keywords
Authors and institutions
- Shandong Key Laboratory of Malignant Tumor Precision Treatment, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
- Research Center for Basic Medical Sciences, Qilu Hospital, Shandong University, Jinan, China.
- Department of Geriatrics, Qilu Hospital, Shandong University, Jinan, China.
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
ORCID profiles: Xiao-Lu Zhang, Tao Li, Zhao-Ru Dong
Funding
- National Natural Science Foundation of China
- Taishan Scholars Program of Shandong Province
- Shandong Provincial Natural Science Foundation
- Natural Science Foundation of Shandong Province
Cite
APA
Zhang, T. S., Xiong, C., Yang, C., Yan, Y. C., Li, J., Li, R. Z., Pan, G. Q., Zou, J., Zhang, X. L., Li, T., & Dong, Z. R. (2026). ADISSP Drives Metabolic Reprogramming and Immune Suppression to Regulate Hepatocellular Carcinoma Progression and Immunotherapy Sensitivity. Advanced Science. https://doi.org/10.1002/advs.78582
Vancouver
Zhang TS, Xiong C, Yang C, Yan YC, Li J, Li RZ, et al. ADISSP Drives Metabolic Reprogramming and Immune Suppression to Regulate Hepatocellular Carcinoma Progression and Immunotherapy Sensitivity. Advanced Science. 2026. doi:10.1002/advs.78582
BibTeX
@article{Zhang2026,
author = {Zhang, Tuan-Song and Xiong, Chen and Yang, Chen and Yan, Yu-Chuan and Li, Jie and Li, Rui-Zhe and Pan, Guo-Qiang and Zou, Jie and Zhang, Xiao-Lu and Li, Tao and Dong, Zhao-Ru},
title = {ADISSP Drives Metabolic Reprogramming and Immune Suppression to Regulate Hepatocellular Carcinoma Progression and Immunotherapy Sensitivity},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78582}
}
EUVIMED